Skip to main content
Clinical Trials/NCT02206971
NCT02206971
Completed
Not Applicable

Biomarker Feedback for Smoking Cessation

Masonic Cancer Center, University of Minnesota1 site in 1 country109 target enrollmentMay 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cigarette Smoking
Sponsor
Masonic Cancer Center, University of Minnesota
Enrollment
109
Locations
1
Primary Endpoint
urinary cotinine level
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

The purpose of this study is to examine the impact of providing light smokers with feedback about their health, including exposure to tobacco-related chemicals.

Detailed Description

The smoking pattern among adults in the US is undergoing a remarkable change. A substantial proportion of smokers are now light smokers (smoke ≤ 10 cigarettes per day), yet little is known about how to help light smokers quit. The prevalence of light smoking is high (\~50%) among African Americans (AAs) who compared to other groups have high cotinine levels, are less successful quitting smoking, and experience disproportionately higher smoking-related cancers. Because light smokers often think that smoking fewer cigarettes a day is safe, a potential smoking cessation strategy is therefore to provide light smokers with feedback on biomarkers of tobacco exposure and increased cancer risk. The objective of this proposal is to develop and pilot test a biomarker risk assessment intervention to enhance smoking cessation for AA light smokers. The proposal builds on our previous work that shows that light smokers have 1) difficulty quitting smoking, 2) lower perceived health risks, but high levels of biomarkers (e.g. cotinine). This study will occur in 2 phases. Phase 1 will utilize focus groups to examine prevailing knowledge, attitudes, and beliefs about biomarkers as well as preferences about how participants would like to receive biomarker feedback (BF; e.g. by mail, phone, in-person). In Phase 2, data from the focus groups will be used to develop a (BF) intervention for light smokers. The new intervention will undergo further feasibility evaluation among 60 adult light smokers. Outcomes in Phase 2 will include process measures, (e.g. perceived usefulness, acceptance, and adherence) and changes in biomarker values with smoking reduction or cessation. By the end of the proposed pilot study, we expect to have developed a replicable, feasible, and acceptable BF intervention that will be ready for efficacy testing in a large clinical trial for smoking cessation or smoking reduction. The aims of the application are to: 1) Examine the prevailing knowledge, attitudes, beliefs, and preferences about BF for smoking cessation among AA light smokers; 2) Develop a BF intervention for smoking cessation among AA light smokers; and 3) Test the feasibility of a BF intervention for smoking cessation in AA light smokers.

Registry
clinicaltrials.gov
Start Date
May 2012
End Date
December 2014
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male or female cigarette smokers, 18-75 years
  • Smoked an average of less than 10 cigarettes per day during past month
  • A personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.

Exclusion Criteria

  • Only one subject per household may participate
  • Pregnancy

Outcomes

Primary Outcomes

urinary cotinine level

Time Frame: week 0, week 8, week 26

changes to biomarker levels with smoking reduction or cessation

Study Sites (1)

Loading locations...

Similar Trials